<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02216071</url>
  </required_header>
  <id_info>
    <org_study_id>EXL CDOS-300 AOE</org_study_id>
    <nct_id>NCT02216071</nct_id>
  </id_info>
  <brief_title>Comparative Efficacy and Safety of Two Ciprofloxacin 0.3% and Dexamethasone 0.1% Formulations in Subjects With Acute Otitis Externa</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Comparative Efficacy and Safety of EXL CDOS in Subjects With Acute Otitis Externa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exela Pharma Sciences, LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exela Pharma Sciences, LLC.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate the clinical therapeutic non-inferiority of EXL
      CDOS to commercially available Ciprofloxacin 0.3% and Dexamethasone 0.1% Sterile Otic
      Suspension (Ciprodex®, Alcon) in the treatment of acute otitis externa (AOE) when
      administered twice daily for 7 days.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Cure of AOE</measure>
    <time_frame>7 days after the completion of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological Cure (MC)</measure>
    <time_frame>7 days after the completion of therapy</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events Monitoring</measure>
    <time_frame>Each monitoring visit through 21 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Otitis Externa</condition>
  <arm_group>
    <arm_group_label>Ciprodex®, RLD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciprodex®, Otic Suspension, Twice daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXL CDOS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension, Otic Suspension, Twice daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprodex®</intervention_name>
    <description>Treatment of acute otitis externa (AOE) when administered twice daily for 7 days</description>
    <arm_group_label>Ciprodex®, RLD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension</intervention_name>
    <description>Treatment of acute otitis externa (AOE) when administered twice daily for 7 days</description>
    <arm_group_label>EXL CDOS</arm_group_label>
    <other_name>Ciprofloxacin 0.3% and Dexamethasone 0.1% Sterile Otic Suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 6 months of age and over;

          2. Clinically documented AOE consistent with the diagnostic guidelines of the American
             Academy of Otolaryngology-Head and Neck Surgery Foundation in 1 or both ears;

          3. Inflammation and/or edema ≥2 on the AOE scale, and otorrhea and/or tenderness present;

          4. AOE of &lt;4 weeks duration;

          5. Intact tympanic membrane(s) in the treated ear(s);

          6. Willingness to refrain from swimming through the TOC/ Visit 5;

          7. For subjects with AOE associated with hearing aid use, willingness to discontinue the
             use of hearing aid(s) in the affected ear(s) through the TOC/Visit 5;

          8. Ability to complete the study in compliance with the protocol;

          9. For adult subjects, ability to understand and provide written informed consent; and

         10. For pediatric subjects, a parent or legal guardian has provided written informed
             consent; and

         11. For children age 6 and above, ability to understand and provide assent according to
             institutional requirements.

        Exclusion Criteria:

          1. Acute or chronic suppurative otitis media;

          2. Post-tympanostomy tube acute otorrhea;

          3. Malignant otitis externa;

          4. Suspected or overt fungal or viral ear infection;

          5. Congenital abnormalities or obstructive bony exostoses of the external auditory canal
             of the treated ear(s);

          6. Seborrheic dermatitis or other dermatologic conditions of the external auditory canal
             of the treated ear(s) which could confound evaluation;

          7. Mastoiditis or other suppurative infectious or non-infectious disorders of the treated
             ear(s);

          8. Malignant tumors of the external auditory canal of the treated ear(s);

          9. History of otologic surgery of the treated ear(s), with the exception of tympanic
             membrane surgery &gt;6 months prior to Baseline;

         10. Four or more episodes of otitis externa (OE) in the previous year;

         11. Uncontrolled diabetes mellitus;

         12. Immunosuppressive disorder, including known Human Immunodeficiency Virus infection;

         13. Renal insufficiency;

         14. Hepatitis or hepatic insufficiency;

         15. Receipt of systemic antibiotic concurrently or within 72 hours prior to Baseline;

         16. Receipt of topical otic antibiotic within 24 hours prior to Baseline;

         17. Use of systemic corticosteroid concurrently or within 30 days prior to Baseline;

         18. Use of topical otic corticosteroids concurrently or within 7 days prior to Baseline;

         19. Concurrent use of systemic or topical otic nonsteroidal or other anti-inflammatory
             drugs;

         20. Use of topical vinegar, alcohol, or other astringent otic preparations concurrently or
             within 24 hours prior to Baseline;

         21. Pregnancy, planned pregnancy, or lactation;

         22. Known sensitivity or intolerance to quinolone antibacterial agents;

         23. Previous participation in this trial;

         24. Participation in another investigational drug or vaccine trial concurrently or within
             30 days; or

         25. Significant acute or chronic medical, neurologic, or psychiatric illness in the
             subject or parent/guardian that, in the judgment of the Principal Investigator, could
             compromise subject safety, limit the subject's ability to complete the study, and/or
             compromise the objectives of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Beck</last_name>
    <phone>706-491-2426</phone>
    <email>jennifer.beck@prnorb.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Piedmont Ear, Nose, and Throat Associates</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Harper</last_name>
      <phone>336-768-3361</phone>
      <phone_ext>146</phone_ext>
      <email>harper27012@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2014</study_first_submitted>
  <study_first_submitted_qc>August 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2014</study_first_posted>
  <last_update_submitted>August 12, 2014</last_update_submitted>
  <last_update_submitted_qc>August 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Externa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

